BUFFALO, N.Y. (WKBW) — Roswell Park Comprehensive Cancer Center announced the FDA has approved of the hospital to perform a clinical trial in an effort to fight COVID-19 in cancer patients.
Researchers will be able to conduct a study assessing the safety and effectiveness of giving both rintatolimod and interferon alfa to cancer patients with COVID-19.
“This is exciting and noteworthy science,” says Roswell Park President and CEO Candace S. Johnson, PhD. “It’s a rare example of a concept for COVID-19 therapy that emerged from academic researchers rather than a pharmaceutical company, and it was a Roswell Park team that looked at the way these two drugs work and saw a possibility for them to enhance each other’s effects — first against cancer and now as a possible treatment for COVID-19.”
Roswell Park says additional clinical sites for the study may be added.
